---
title: "Ifezuntirgene inilparvovec (AMT-130): Huntington's disease"
description: "Formulary evidence on Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease. Clinical evidence covers Pooled phase I/II analysis versus external control, CT-AMT-130-01, CT-AMT-130-02, and Planned confirmatory trial. 648 evidence topics quoted from 291 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Ifezuntirgene inilparvovec (AMT-130): Huntington's disease

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Ifezuntirgene inilparvovec

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of Huntington's disease

<a id="topic-1.1.1-1"></a>

##### Summary: definition, epidemiology, natural history, and mortality

Huntington's disease (HD) is an autosomal dominant, progressive disorder of motor, cognitive, and psychiatric manifestations caused by an expanded CAG trinucleotide repeat in HTT, the gene that encodes huntingtin. Offspring of an individual with the expansion have a 50% chance of inheriting it. Penetrance is variable for alleles carrying 36-39 repeats, and the disease appears fully penetrant when the repeat numbers are >40.

- Incidence: pooling 33 studies published between 2010 and 2022 reported a pooled incidence of 0.48 cases per 100,000 person-years (95% CI, 0.33-0.63). In an insurance database cohort of 3,707 individuals diagnosed between 2003 and 2016, the cumulative incidence rate was 1.22 per 100,000 person years. In the Medicare population, 819 incident cases were identified in 2017, an incidence rate of 6.1 per 100,000 person-years.
- Prevalence: the pooled prevalence was 4.88 per 100,000 (95% CI, 3.38-7.06). In populations of European ancestry, the average prevalence is 9.71 per 100,000, with up to 17 per 100,000 when multiple sources of ascertainment are accounted for. The prevalence proportion was 13.1 per 100,000 in the Medicare population in 2017 and 15.2 per 100,000 in the Medicaid population in 2014. The Huntington's Disease Society of America states that approximately 41,000 Americans are symptomatic and more than 200,000 are at risk of inheriting the disease; the sponsor states that approximately 75,000 people have HD in the U.S., EU, and UK, with approximately 40,000 symptomatic patients in the U.S.
- Natural history: the mean age of onset is approximately 45 years, and subtle changes can occur as early as 15-20 years before clinical onset. In approximately 25% of individuals, onset is delayed until after age 50 years. The proportion with juvenile HD, defined by onset of symptoms before age 20 years, varies from 1% to 15% of individuals diagnosed with HD. In 960 participants with definite HD followed prospectively for a mean of 18.3 months, the Total Functional Capacity (TFC) score declined at 0.72 units/year (SE 0.04). The median survival time after onset is 15 to 18 years (range: 5 to >25 years), and the average age at death is 54 to 58 years.
- Mortality: in one cohort, individuals with HD had a hazard ratio for death of 4.51 (95% CI 3.36–6.06) relative to controls after multivariable adjustment, with a median age at death of 71 years compared with 81 years in controls. In one study, the mean age at death was 63.9 years (NCDR) and 61.7 years (CRD) compared with 76.9 years in the general population; HD was the underlying cause of death in 73.5% of individuals, respiratory diseases were the most common immediate cause (44.2%), and suicide accounted for 2.3% of deaths compared with 1.3% in the general population. In a chart review, 86.8% of patients whose cause of death could be identified died from aspiration pneumonia.

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/); [Bates et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/27188817/); [Bean et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/25356969/); [Medina et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10086981/); [Bruzelius et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6579693/); [Exuzides et al. (2022b)](https://pubmed.ncbi.nlm.nih.gov/35483335/); [Huntington's Disease Society of America (2020)](https://hdsa.org/what-is-hd/overview-of-huntingtons-disease/); [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm); [Marder et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10668713/); [Furby et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9542098/); [Solberg et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5870025/); [Heemskerk and Roos (2012)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3269785/)

<a id="topic-1.1.1-2"></a>

##### Summary: symptoms and long-term morbidity

- Motor: chorea is the major sign of HD and is present in most individuals. With advancing disease, chorea may decrease and bradykinesia, rigidity, and dystonia occur; oculomotor disturbances occur in up to 75% of symptomatic individuals.
- Cognitive: a global and progressive decline in cognitive capabilities occurs in all individuals with HD, often beginning with loss of mental flexibility and impairment of executive functions.
- Psychiatric: depression affects 40% of individuals with HD. In one study, ninety-eight per cent of patients exhibited neuropsychiatric symptoms, most commonly dysphoria, agitation, irritability, apathy, and anxiety. Apathy was present in 32% of preHD-A participants and 62% of early-HD patients.
- Other: swallowing difficulties can lead to choking episodes and aspiration pneumonia, and individuals with HD tend to experience substantial weight loss.
- Morbidity: in late stages, the individual is often totally dependent, mute, and incontinent. In one study, 27 participants (60%) reported two or more falls in the previous year. Among 3,070 individuals with clinically definite HD, 228 (7.4%) resided in skilled nursing facilities, and bradykinesia, impaired gait, and impaired tandem walking predicted placement. Across studies, depression (median r=0.48) and apathy (median r=0.47) were the symptoms most commonly associated with decreased functional capacity.

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/); [Paulsen et al. (2001)](https://pmc.ncbi.nlm.nih.gov/articles/PMC1737562/); [Martinez-Horta et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26898966/); [Grimbergen et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18381643/); [Wheelock et al. (2003)](https://pubmed.ncbi.nlm.nih.gov/12654967/); [Sellers et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/31466515/)

<a id="topic-1.1.1-3"></a>

##### Summary: humanistic burden

- In a study of 2,094 people with HD, the mean EQ-5D-5L utility score (n = 336) was 0.59 (SD, 0.27), with mean scores of 0.72 in early stage, 0.62 in middle stage, and 0.37 in advanced stage disease; the mean SF-6D score (n = 482) was 0.57. Current suicidal ideation was reported by 13% and previous suicidal ideation by 28% of participants, and 91% of 482 questionnaire respondents reported difficulty sleeping.
- A review of 383 screened articles, covering 11 distinct studies, reported an EQ-5D index range of 0.89 - 0.72 for mild or prodromal HD and 0.71 - 0.37 for severe or late-stage disease, with high variability in published estimates.
- In a study of 84 participants, mean HRQoL values were 0.84 in the early phase, 0.74 in the middle phase, and 0.65 in the advanced phase.
- In a survey, individuals with HD had a mean EQ-5D of 0.66 compared with 0.81 in the general population cohort, and 51.2% had comorbid anxiety.
- In time trade-off valuations of chorea health states, utility values were 0.07 for severe chorea and 0.64 for mild chorea.
- Functional capacity and depressive mood were significantly associated with health-related quality of life; motor symptoms and cognitive function were less closely linked.

Source: [Rodriguez Santana et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9757103/); [Rodríguez Santana et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11962051/); [Sawant et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11020898/); [van Walsem et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9753307/); [Exuzides et al. (2022a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8869871/); [Claassen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8990962/); [Ho et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19097181/)

<a id="topic-1.1.1-4"></a>

##### Summary: economic burden

- In a study of 3,688 matched pairs of beneficiaries with and without HD, mean annual total healthcare costs were $41,631 with HD and $17,222 without, driven primarily by outpatient pharmacy costs; by stage, mean costs were $20,475 in early-stage, $29,733 in middle-stage, and $56,657 in late-stage HD.
- In a matched study of 595 beneficiaries with HD and 1,785 without, mean annual total costs were $73,087 and $26,834, respectively, driven by inpatient costs; costs were $95,251 in late-stage HD.
- In commercial and Medicaid claims data from 1272 individuals with HD, the mean total annualized cost per patient increased by stage (commercial: $4947 to $22,582; Medicaid: $3257 to $37,495), and 73.8% of Medicaid late-stage patients received nursing home care.
- In another study, mean total costs (2018 USD per patient per month) were $2,260 for individuals with HD and $1,056 for matched non-HD controls.
- In the HDBOI study (2020 euros), cost estimates were €12,663 for direct medical costs, €2984 for nondirect medical costs, and €47,576 for indirect costs; total costs were €62,372, ranging from €42,477 in early stage to €86,177 in advanced stage. Indirect costs accounted for 84%, 80%, and 66% of early, middle, and advanced stage total costs. In the USA, direct medical costs were €27,743 and indirect costs were €74,228.
- In one cohort, 89.8% of patients with a TFC score of 7–10 were unemployed, and fewer than 20% remained employed 4 years after clinical diagnosis.

Source: [Exuzides et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34730477/); [Patel et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37285853/); [Divino et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23789925/); [To et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10373050/); [Rodríguez-Santana et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36421029/); [Ko et al. (2020)](https://www.mdsabstracts.org/abstract/burden-of-huntingtons-disease-hd-on-loss-of-employment-status-and-its-association-with-disease-stage/)

<a id="topic-1.1.1-5"></a>

##### Summary: caregiver and family burden

- In the UK, the mean annual cost per person with HD was £21,605, of which 65% (£14,085) was due to informal care, and informal care was the largest cost driver across all stages. In another study, informal care costs (€30,605 over six months) accounted for approximately half of total societal costs. A synthesis of five cost studies reported annual caregiver costs ranging from $6041 in early stage to $133,200 in late-stage HD.
- In one caregiver survey, respondents reported an average of 34 hours of informal care per week; 37 (7%) had stopped working because of caregiving and 206 (41%) reported an impact on their career. Impairment in caregiver daily activities was 42%, 48%, and 52% for early, middle, and advanced stage disease.
- In one study, 80 informal caregivers provided a mean of 7.3 hours of informal care per day. In another, 55.3% of care partners experienced high strain. In a survey, depression was reported by 65.0% of HD care partners compared with 19.6% of general population care partners.
- Higher caregiver burden was associated with total functional capacity and being the sole caregiver in one study, and with a more severe Shoulson-Fahn stage in another. Stakeholder input to ICER states that 24/7 care is eventually needed, particularly during the last five years of life.
- Across the United States, Canada, and Australia, 46.2% of surveyed respondents reported genetic discrimination or stigma, including 25.9% in the domain of insurance.

Source: [Jones et al. (2016)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5096063/); [van Walsem et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9753307/); [Patil et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11717757/); [Willock et al. (2021)](https://www.ispor.org/docs/default-source/euro2021/ispor-wpai-caregiver-poster-final-version-pdf.pdf); [Bayen et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36055643/); [Shaw et al. (2022b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9277690/); [Exuzides et al. (2022a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8869871/); [Yu et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30594932/); [Lee et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10846961/); [ICER draft scope (2026)](https://icer.org/wp-content/uploads/2026/08/Huntingtons-Disease_Draft-Scope_For-Publication_082026_For-Publication.pdf); [Erwin et al. (2010)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3593716/)

<a id="heading-1.1.2"></a>

#### 1.1.2 Ifezuntirgene inilparvovec Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary: design of the source studies and the pooled analysis

- Ifezuntirgene inilparvovec (AMT-130) is given once, by MRI-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum (caudate and putamen). The registry records list a low dose of 6x10^12 gc/subject and a high dose of 6x10^13 gc/subject.
- CT-AMT-130-01 (United States): in Cohorts 1 and 2, 26 participants with early manifest Huntington's disease were randomized to the low dose (6), the high dose (10), or an imitation (sham) surgical procedure (10), with a blinded 12-month period followed by unblinded long-term follow-up. In Cohort 3, 12 participants were blinded and randomized to the high dose (n=6) or the low dose (n=6) with an immunosuppression regimen. Cohort 4 enrolled six participants with lower striatal volumes, all receiving the high dose. The registered primary outcome is adverse events, assessed at 12 months.
- CT-AMT-130-02 (Europe): the Form 10-K reports 13 participants enrolled and treated in this open-label study (six low dose, seven high dose); the ClinicalTrials.gov record lists an actual enrollment of 14.
- Pooled analysis: two additional protocols pool data across the U.S. and EU studies and prespecify a comparison with a propensity score-matched external control from the Enroll-HD natural history data set. Matching covariates were baseline age, sex, CAP100, DCL, TFC, TMS, SDMT, and SWR. Eligibility required age 25-65 years, TFC 9-13, and striatal volumes above specified minima. The primary endpoint is change from baseline in cUHDRS at 36 months; secondary endpoints are TFC, SDMT, SWRT, and TMS; CSF NfL change at 36 months is supportive.
- Primary comparison: the June 2025 release described a propensity score-weighted external control for the primary analysis, with a propensity score-matched control as a sensitivity analysis; the September 2025 release reports the propensity score-matched comparison as the prespecified primary analysis.
- Participants: the three-year analysis (data cutoff June 30, 2025) covered 29 treated participants (17 high dose, 12 low dose), of whom 12 per dose group had 36 months of follow-up, against Enroll-HD controls of n=940 (high dose) and n=626 (low dose). The four-year and updated 36-month analyses (data cutoff June 30, 2026) used an updated Enroll-HD dataset with a September 2025 cutoff (n=1,337 for high dose, Enroll-HD B) for the primary comparison and the earlier dataset (Enroll-HD A, N=619) for a post hoc comparison.

Source: [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm); [ClinicalTrials.gov NCT04120493](https://clinicaltrials.gov/study/NCT04120493); [ClinicalTrials.gov NCT05243017](https://clinicaltrials.gov/study/NCT05243017); [uniQure press release, enrollment of first two cohorts (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-completion-patient-enrollment-first-two); [uniQure press release, first quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-quarter-2025-financial-results-and); [uniQure press release, full year 2025 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-2025-financial-results-and-provides-recent); [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf); [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf); [uniQure press release, statistical analysis plan and CMC alignment (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease); [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii); [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies); [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf)

<a id="topic-1.1.2-2"></a>

##### Summary: efficacy versus the Enroll-HD external control at 36 and 48 months

- Three-year analysis, high dose (12 participants at 36 months; data cutoff June 30, 2025): mean change in cUHDRS from baseline was -0.38 compared with -1.52 for the propensity score-matched external control, a 75% slowing of disease progression (p=0.003), which met the primary endpoint. Mean change in TFC was -0.36 compared with -0.88, a 60% slowing (p=0.033), which met a key secondary endpoint. SDMT showed an 88% slowing (p=0.057; -0.44 compared with -3.73). The Form 10-K reports a 113% slowing on SWRT (nominal p=0.002; 0.88 compared with -6.98) and a 59% slowing on TMS (nominal p=0.174; 2.01 compared with 4.88). Mean CSF NfL changed by -8.2% from baseline (N=11 in the presentation).
- Three-year analysis, low dose (N=12): LSM change in cUHDRS was -1.65 compared with -1.72 for the external control (difference 0.07 [95% CI -0.75, 0.88]; p=0.871). The TFC difference was 0.71 [0.12, 1.31] (p=0.019), and LSM change in SDMT was -6.44 compared with -3.35 (difference -3.09; p=0.046). The presentation states that these p-values are nominal and that hierarchical testing was discontinued for p-value >0.05. Mean CSF NfL changed by -4.7%. The company attributes the contrast between doses to a “dose-dependent response”.
- Updated 36-month analysis, high dose (15 participants; data cutoff June 30, 2026; Enroll-HD B): cUHDRS changed by -0.28 compared with -1.39, an 80% slowing (nominal p=0.005); TFC changed by -0.27 compared with -0.82, a 67% slowing (nominal p=0.011). The presentation reports slowing of 124% on SDMT (p=0.040), 123% on SWRT (p=0.047), and 59% on TMS (p=0.114), with nominal p-values. Mean CSF NfL was 6% below baseline (n=14).
- 48-month primary analysis, high dose (12 participants; Enroll-HD B): cUHDRS changed by -0.90 compared with -1.61, a 44% slowing that did not reach statistical significance (p=0.144). TFC changed by -0.37 compared with -0.94, a 61% slowing (nominal p=0.008). The presentation reports slowing of 113% on SWRT (p=0.006), 20% on SDMT (p=0.731), and 5.6% on TMS (p=0.908). Mean CSF NfL was 4% above baseline for the high dose (n=11) and 8% below baseline for the low dose.
- 48-month post hoc analysis against Enroll-HD A (N=619): the release reports 53.5% slowing on cUHDRS (nominal p=0.041) and 68.3% on TFC (nominal p=0.001); the presentation reports 54% (p=0.041) and 68% (p<0.001).
- Dose comparison at 48 months: the four-year release reports mean change in cUHDRS of -0.91 for the high dose and -1.94 for the low dose (a difference of 1.03) and in TFC of -0.30 and -0.70 (a difference of 0.40); the third quarter 2026 release reports 1.1 points less decline on cUHDRS and 0.33 points less decline on TFC for the high dose.
- Missing data in the updated Enroll-HD matched controls reached 53% at 48 months, and the company states that this likely understated progression in the control group.

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii); [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf); [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm); [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies); [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf); [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

<a id="topic-1.1.2-3"></a>

##### Summary: interim comparisons with other natural history controls, 2023 and 2024

- December 2023 (data cutoff September 30, 2023): treated participants were compared with a non-concurrent criteria-matched cohort of 31 participants from the TRACK-HD natural history study, excluding efficacy data from control participants who crossed over to treatment. The favorable difference in cUHDRS was 0.39 points at 30 months for the low dose and 1.24 points at 18 months for the high dose; for TFC it was 0.95 points at 30 months and 0.49 points at 18 months.
- July 2024 (data cutoff March 31, 2024; 24-month data from 21 participants, 12 low dose and 9 high dose): compared with a propensity-weighted external control (n=154) from the TRACK-HD, TRACK-ON, and PREDICT-HD studies, mean change in cUHDRS was -0.2 for the high dose and -1.0 for the control, an 80% slowing (p=0.007), and -0.7 for the low dose, a 30% slowing (p=0.21). Mean CSF NfL was reduced by 11% from baseline (p=0.02). The Form 10-K describes this comparison as a post-hoc analysis.

Source: [uniQure press release, interim data update (2023)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-update-phase-iii-clinical-trials-amt-130-gene); [uniQure press release, 24-month interim data (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-interim-data-update-demonstrating); [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm)

<a id="topic-1.1.2-4"></a>

##### Summary: safety

- The most common adverse events in the treatment groups were related to the administration procedure, and all resolved.
- June 30, 2025 data cutoff (Cohorts 1 to 3, n=45 treated; sham surgery n=10): any treatment-emergent adverse event occurred in 44 (97.8%) treated participants, any serious adverse event in 15 (33.3%), a peri-operative serious adverse event in 8 (17.8%), a drug-related adverse event in 9 (20.0%), and a drug-related serious adverse event in 4 (8.8%); 1 (10.0%) sham participant had a serious adverse event. The most frequent events among treated participants were headache (18, 40.0%), procedural headache (16, 35.6%), procedural pain (11, 24.4%), and post lumbar puncture syndrome (10, 22.2%).
- June 30, 2026 data cutoff (Cohorts 1 to 4, n=51 treated): any treatment-emergent adverse event 50 (98%), any serious adverse event 20 (39.2%), peri-operative serious adverse event 9 (17.6%), drug-related adverse event 11 (21.5%), drug-related serious adverse event 5 (9.80%), and headache 21 (41.2%).
- Central nervous system inflammation: in July 2022 the company reported suspected unexpected severe adverse reactions in three of the 14 participants treated with the high dose, and in October 2022 the Data Safety Monitoring Board recommended resuming the high dose with additional risk mitigation procedures during the first two weeks after administration. The four-year release states that five high dose participants (17%) experienced a treatment-related serious adverse event related to central nervous system inflammation, all of which fully resolved. The four-year presentation reports one such event in a Cohort 4 participant, which resolved after a short course of corticosteroids.
- In Cohort 3, three serious adverse events related to immunosuppression (mania, infection, and fever) resolved with supportive care, and no treatment-related serious adverse events were reported.
- One low-dose participant died by suicide approximately five years after treatment; the study investigator assessed the event as unrelated to treatment.

Source: [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii); [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf); [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies); [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf); [uniQure press release, second quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2022-financial-results-and); [uniQure press release, third quarter 2022 results (2022)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2022-financial-results-and); [uniQure press release, first quarter 2025 results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-first-quarter-2025-financial-results-and)

<a id="topic-1.1.2-5"></a>

##### Summary: regulatory context for the external control comparison

- In 2024 the company reported that, at a Type B meeting held in late November, the FDA agreed that phase I/II data compared with a natural history external control may serve as the primary basis for a BLA under the Accelerated Approval pathway, with cUHDRS as an intermediate clinical endpoint and CSF NfL reductions as supportive evidence.
- After the October 29, 2025 pre-BLA meeting, the company stated its belief that the FDA no longer agreed that the external control comparison may be adequate as primary evidence, and the final minutes stated that the phase I/II data were “currently unlikely to provide the primary evidence” to support a BLA submission. After a Type A meeting on January 30, 2026, the FDA stated that it cannot agree that these data are sufficient and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study.
- After a Type B meeting, the company reported in 2026 that the FDA communicated that the 3-year analysis would be acceptable as the primary basis of a BLA for accelerated approval, and minutes received in July 2026 confirmed that a submission based on the existing clinical data is reasonable.
- The Form 10-Q states that the company announced the BLA submission in September 2026 and, in a separate passage, that the BLA was submitted in August 2026 and accepted in October 2026; it also states that acceptance was announced on November 2, 2026. The application has Priority Review with a PDUFA target action date of May 1, 2027, and the FDA is tentatively planning an Advisory Committee meeting. The BLA is supported by 36-month data from 12 high-dose participants compared with a propensity score-matched external control, and the 48-month results were not part of the BLA or the UK MAA, which the MHRA validated in the third quarter of 2026.
- The confirmatory trial is designed as a randomized, standard-of-care-controlled trial of approximately 200 participants randomized 2:1, with TFC at 36 months as the primary endpoint; screening is planned to begin in the United States by the end of 2026.

Source: [uniQure press release, FDA alignment on accelerated approval (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-alignment-fda-key-elements-accelerated); [uniQure press release, pre-BLA meeting feedback (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-0); [uniQure press release, pre-BLA meeting minutes (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-1); [uniQure press release, Type A meeting minutes (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-2); [uniQure press release, BLA plan after Type B meeting (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-plan-bla-submission-amt-130-huntingtons); [uniQure press release, second quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-second-quarter-2026-financial-results-and); [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm); [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics); [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Ifezuntirgene inilparvovec

<a id="topic-1.1.3-1"></a>

##### Summary

ICER's model analysis plan uses a placeholder price for AMT-130, and the report holds no budget impact model for the product. The inputs on which a plan's budget would depend are available from ICER's model analysis plan, analyst estimates, and published prices of approved gene therapies.

- Eligible population: ICER multiplies a U.S. prevalence of approximately 40,000 people in 2020 (a prevalence rate of approximately 0.012%) by the approximately 62.7% of people with Huntington's disease in SF stage 1 or 2 and applies it to a U.S. population of approximately 342 million averaged over 2026-2030, giving 25,811 eligible patients. ICER assumes that 20% of these patients would initiate treatment in each of the five years, or 5,162 patients per year. An exploratory preclinical population of 100,000 people, with 20,000 initiating treatment per year, is derived from approximately 200,000 people at risk and the 50% likelihood of inheriting the mutation. In a study population of 38.4 million individuals who met a continuous enrollment requirement, the prevalence rate was 6.7 per 100,000 in 2020 and 9.4 per 100,000 in 2024.
- Price: Leerink analysts estimated a U.S. price of $1.7 million if approved. ICER cites estimates ranging from $1,700,000 by Leerink Partners to $2,500,000 - $3,500,000 by IPD analytics and uses the midpoint of $2,600,000 as a placeholder price, with an administration price of $24,138.83.
- Budget impact method: ICER will estimate budget impact at the placeholder price and at threshold prices of $50,000, $100,000, $150,000, and $200,000 per evLY gained, with undiscounted costs over a five-year time horizon. Its potential budget impact threshold for 2026-2027 is approximately $709 million per year for new drugs.
- Comparator prices: Zolgensma, a one-time treatment, launched at a list price of $2.125 million, the gene therapy Hemgenix at $3.5 million, Roctavian at a wholesale acquisition cost of $2.9 million, the gene therapy Elevidys at a wholesale acquisition cost of $3.2 million, and the gene therapy Beqvez at $3.5 million; the U.S. wholesale acquisition cost of eladocagene exuparvovec-tneq is $3,950,000. A pharmacist quoted at the Elevidys launch stated that gene therapy prices range from $2.1 million to $3.5 million. BioMarin announced that it will voluntarily remove Roctavian from the market, and Beqvez was discontinued.
- Reference budget impact analysis: in a CSL Behring-funded analysis of etranacogene dezaparvovec at $3,500,000 in a hypothetical 1-million-member plan, an estimated 1.8 people were eligible, and gradual uptake produced a cumulative 5-year budget impact of $848,509, with incremental per-member per-month costs of $0.007 to $0.023; 100% uptake in year 1 produced an incremental annual cost of $4.843 million or $0.40 PMPM.

Source: [ICER model analysis plan (2026)](https://osf.io/download/puega/); [Bell (2026)](https://www.biopharmadive.com/news/uniqure-huntingtons-four-year-data-gene-therapy-results/831611/); [Frisch et al. (2026)](https://www.jmir.org/2026/1/e100284); [Helfand (2019)](https://www.fiercepharma.com/pharma/novartis-slaps-2m-plus-pricetag-newly-approved-gene-therapy-zolgensma); [Myshko (2022)](https://www.managedhealthcareexecutive.com/view/fda-approves-gene-therapy-for-hemophilia-b); [Myshko (2023)](https://www.managedhealthcareexecutive.com/view/fda-approves-2-9-million-gene-therapy-for-hemophilia-a); [Blank (2023)](https://www.managedhealthcareexecutive.com/view/first-gene-therapy-for-duchenne-priced-at-3-2-million); [Myshko (2024)](https://www.managedhealthcareexecutive.com/view/fda-approves-pfizer-s-gene-therapy-for-beqvez-for-hemophilia); [Zhang et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12799622/); [BioMarin statement, ROCTAVIAN market withdrawal (2026)](https://www.biomarin.com/news/company-statements/biomarin-voluntarily-withdraws-roctavian-from-the-market/); [Liu (2025)](https://www.fiercepharma.com/pharma/pfizer-empties-gene-therapy-portfolio-discontinues-hemophilia-treatment-beqvez); [Wilson et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11293766/)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

Huntington's disease (HD) is an autosomal dominant, progressive disorder of motor, cognitive, and psychiatric manifestations, with a median survival time after onset of 15 to 18 years. The sponsor states that approximately 75,000 people have HD in the U.S., EU, and UK, with approximately 40,000 symptomatic patients in the U.S. The Huntington's Disease Society of America states that there is currently no cure or treatment that can halt, slow, or reverse progression of the disease, and the sponsor states that there are currently no approved therapies to delay the onset or slow the progression of HD.

Ifezuntirgene inilparvovec (AMT-130) is given as a single administration by MRI-guided, convection-enhanced stereotactic neurosurgical delivery into the striatum (caudate and putamen). Its efficacy evidence consists of pooled data from the U.S. phase I/II and European phase Ib/II studies compared with a propensity score-matched external control from the Enroll-HD natural history data set. In the three-year analysis (data cutoff June 30, 2025), 29 participants had been treated (17 high dose, 12 low dose), and 12 per dose group had 36 months of follow-up. In the high-dose group, mean change in cUHDRS from baseline was -0.38 compared with -1.52 for the external control, a 75% slowing of disease progression (p=0.003) that met the primary endpoint, and TFC showed a 60% slowing (p=0.033); in the low-dose group, mean change in cUHDRS was -1.65 compared with -1.72 (p=0.871). At 48 months, against an updated external control, the 12 high-dose participants showed a 44% slowing on cUHDRS that did not reach statistical significance (p=0.144) and a 61% slowing on TFC (nominal p=0.008). The most common adverse events were related to the administration procedure, and all resolved. Five high dose participants (17%) experienced a treatment-related serious adverse event related to central nervous system inflammation, all of which fully resolved; in the four-year presentation's cumulative safety table, 20 (39.2%) treated participants had any serious adverse event and 5 (9.80%) a drug-related serious adverse event. One low-dose participant died by suicide approximately five years after treatment, which the study investigator assessed as unrelated to treatment.

The BLA was submitted under the Accelerated Approval pathway and has Priority Review with a PDUFA target action date of May 1, 2027; the FDA stated that it is tentatively planning to discuss the application at an Advisory Committee meeting. The Form 10-Q states that the BLA was submitted in August 2026 and accepted in October 2026, and that acceptance was announced on November 2, 2026. The BLA is supported by 36-month data from 12 high-dose participants compared with a propensity score-matched external control. The FDA's position on this evidence changed over time: at a Type B meeting held in late November, as the company reported in 2024, it agreed that the phase I/II data compared with a natural history external control may serve as the primary basis for a BLA under the Accelerated Approval pathway; after a pre-BLA meeting held on October 29, 2025, it conveyed that the data “are currently unlikely to provide the primary evidence” to support a BLA submission; after a Type A meeting held on January 30, 2026, it stated that it cannot agree that the data are sufficient and strongly recommended a prospective, randomized, double-blind, sham surgery-controlled study; and after a subsequent Type B meeting, it communicated that the 3-year analysis would be acceptable as the primary basis of a BLA for accelerated approval. The confirmatory study is designed as a randomized, standard-of-care-controlled trial enrolling approximately 200 participants randomized 2:1, with TFC as the primary endpoint at 36 months, and patient screening is planned to begin in the U.S. by the end of 2026.

ICER's model analysis plan uses a placeholder price of $2,600,000, the midpoint of a $1,700,000 lower value (Leerink Partners) and a $3,500,000 upper value (IPD analytics), with an administration price of $24,138.83. A published cost-effectiveness analysis assumed the cost of AMT-130 to be the list price of Zolgensma less a 15% payer discount ($1,806,250); compared with standard of care, AMT-130 increased costs by $1.49 million and QALYs by 5.23, an incremental cost-effectiveness ratio of $285,703 per QALY gained. ICER estimates 25,811 eligible patients in the US from a prevalence of approximately 40,000 people and the approximately 62.7% in SF stage 1 or 2, and assumes that 20% initiate treatment in each of five years (5,162 patients per year).

The limitations summaries name the following uncertainties. The analyses rely on external historical controls, which the Form 10-K states may not be accepted as a basis for regulatory approval, and one commentary noted that the evidence of efficacy “depends entirely on the ENROLL-HD controls being well-matched”. MRI data were not collected in Enroll-HD, so striatal volume could not be matched; most participants were in open-label arms, so a placebo effect is possible; 12 high-dose participants contributed 36-month data to the three-year analysis, 15 to the updated 36-month analysis, and 12 to the 48-month analysis; data missingness in the updated Enroll-HD matched controls reached 53% at 48 months; and several p-values are nominal. The results are reported in company press releases, presentations, and SEC filings. ICER's base case assumes that the treatment effect remains constant over the lifetime horizon, and the authors of the published cost-effectiveness analysis state that their model relied heavily on the assumption of sustained benefit beyond the data.

Source: [Caldeira Brás et al. (2026)](https://www.ncbi.nlm.nih.gov/books/NBK1305/); [uniQure Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/qure-20251231x10k.htm); [Huntington's Disease Society of America (2011)](https://hdsa.org/wp-content/uploads/2015/03/PhysiciansGuide_3rd-Edition.pdf); [uniQure press release, BLA submission (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-submission-biologics-license-application); [uniQure press release, three-year topline results (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-positive-topline-results-pivotal-phase-iii); [uniQure presentation, three-year topline results (2025)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Pivotal-Sept-2025_final_09.24.25.pdf); [uniQure press release, four-year data (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-additional-data-ongoing-phase-iii-studies); [uniQure presentation, four-year data (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/AMT-130-Sept-2026-Data-Update_Final.pdf); [uniQure press release, FDA acceptance of BLA (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-fda-acceptance-and-priority-review-biologics); [uniQure Form 10-Q, third quarter 2026 (2026)](https://www.sec.gov/Archives/edgar/data/1590560/000110465926122367/qure-20260930x10q.htm); [uniQure press release, third quarter 2026 results (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-third-quarter-2026-financial-results-and); [uniQure press release, FDA alignment on accelerated approval (2024)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-alignment-fda-key-elements-accelerated); [uniQure press release, pre-BLA meeting minutes (2025)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-1); [uniQure press release, Type A meeting minutes (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-provides-regulatory-update-amt-130-huntingtons-disease-2); [uniQure press release, BLA plan after Type B meeting (2026)](https://uniqure.gcs-web.com/news-releases/news-release-details/uniqure-announces-plan-bla-submission-amt-130-huntingtons); [ICER model analysis plan (2026)](https://osf.io/download/puega/); [Patil et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42665725/); [Margolin et al. (2026)](https://cdn.craft.cloud/fe68e1a2-b284-4f69-ba29-921f065edf17/assets/uploads/CHDI-2026Feb-AMT-130-striatal-volumes-FINAL-PDF.pdf); [Minikel (2025)](https://www.cureffi.org/2025/10/08/amt-130/)

## Related pages
- [Ifezuntirgene inilparvovec (AMT-130): Huntington's disease](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Terms and abbreviations](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/terms-and-abbreviations.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Product information and disease description](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/product-information-and-disease-description.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Clinical evidence](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/clinical-evidence.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: Economic information and modeling report](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/economics.md)
- [Ifezuntirgene inilparvovec (AMT-130) in Huntington's disease: References](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references) · [Markdown](https://www.evicenter.com/drugs/ifezuntirgene-inilparvovec--huntington-s-disease/references.md)
